Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?Zacks Investment Research • 04/22/25
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticariaGlobeNewsWire • 04/18/25
Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory IndicationsZacks Investment Research • 04/16/25
Press Release: Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPDGlobeNewsWire • 04/15/25
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug ImportsInvestors Business Daily • 04/09/25
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosisGlobeNewsWire • 04/08/25
SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare DiseasesZacks Investment Research • 04/03/25
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicinesGlobeNewsWire • 04/03/25
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United StatesZacks Investment Research • 04/01/25
Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitorsGlobeNewsWire • 03/28/25
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDGlobeNewsWire • 03/28/25